Marin J, et al. - Experts evaluated the effectiveness, safety and place in therapy of certolizumab pegol (CZP), a pegylated humanized tumour necrosis factor-α inhibitor (TNFi), in the treatment of axial spondyloarthritis (axSpA) with special considerations of CZP during pregnancy. They conducted a Phase III trial in patients with AS and nr-axSpA as double-blind and placebo-controlled to week 24, dose-blind to week 48 and open-label to week 204. Findings suggested the efficacy of CZP, the latest TNFi to be approved, in all manifestations of AS and nr-axSpA. The patients treated with CZP, improvements in axial involvement, joint involvement, enthesitis and quality of life were seen. Similar safety profile as that reported for other TNFi in axSpA patients was seen.